X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (38) 38
male (30) 30
index medicus (28) 28
aged (27) 27
middle aged (26) 26
female (25) 25
hematology (22) 22
adult (14) 14
prognosis (14) 14
bortezomib (12) 12
multiple myeloma - drug therapy (12) 12
treatment outcome (12) 12
oncology (11) 11
disease-free survival (10) 10
elderly-patients (10) 10
thalidomide - administration & dosage (10) 10
diagnosis (9) 9
lenalidomide (9) 9
multiple myeloma - mortality (9) 9
retrospective studies (9) 9
risk factors (9) 9
stem-cell transplantation (9) 9
transplantation (9) 9
aged, 80 and over (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
multiple myeloma (8) 8
thalidomide (8) 8
boronic acids - administration & dosage (7) 7
hematology, oncology and palliative medicine (7) 7
pyrazines - administration & dosage (7) 7
survival (7) 7
chemotherapy (6) 6
hematopoietic stem cell transplantation (6) 6
internal medicine (6) 6
kaplan-meier estimate (6) 6
mortality (6) 6
multivariate analysis (6) 6
recurrence (6) 6
therapy (6) 6
abridged index medicus (5) 5
analysis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
care and treatment (5) 5
dexamethasone (5) 5
follow-up studies (5) 5
immunology (5) 5
medicine & public health (5) 5
melphalan - administration & dosage (5) 5
patients (5) 5
prednisone - administration & dosage (5) 5
prednisone plus thalidomide (5) 5
research (5) 5
thalidomide - analogs & derivatives (5) 5
acute disease (4) 4
antineoplastic agents - administration & dosage (4) 4
bone-marrow-transplantation (4) 4
boronic acids - adverse effects (4) 4
bortezomib-melphalan-prednisone (4) 4
criteria (4) 4
hematopoietic stem cells (4) 4
infectious diseases (4) 4
initial treatment (4) 4
italy - epidemiology (4) 4
medicine (4) 4
melphalan - adverse effects (4) 4
multiple myeloma - diagnosis (4) 4
prednisone - adverse effects (4) 4
pyrazines - adverse effects (4) 4
risk (4) 4
survival analysis (4) 4
thalidomide - adverse effects (4) 4
thalidomide - therapeutic use (4) 4
transplantation, autologous (4) 4
versus-host-disease (4) 4
[phys.astr]physics [physics]/astrophysics [astro-ph] (3) 3
antineoplastic agents - therapeutic use (3) 3
astrophysics (3) 3
blood (3) 3
cancer (3) 3
clinical-trials (3) 3
graft vs host disease - immunology (3) 3
guidelines (3) 3
high energy astrophysical phenomena (3) 3
in situ hybridization, fluorescence (3) 3
incidence (3) 3
lenalidomide plus dexamethasone (3) 3
lymphoma (3) 3
magnetic spectrometer (3) 3
maintenance therapy (3) 3
melphalan (3) 3
metaanalysis (3) 3
multiple myeloma - complications (3) 3
multiple myeloma - therapy (3) 3
multiple-myeloma (3) 3
oral melphalan (3) 3
physics (3) 3
predictive value of tests (3) 3
prognostic-factors (3) 3
proportional hazards models (3) 3
pulmonary embolism (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal Article
Mediterranean Journal of Hematology and Infectious Diseases, ISSN 2035-3006, 2018, Volume 10, Issue 1, pp. e2018001 - e2018001
Hepatic Veno-Occlusive Disease (VOD) is a potentially severe complication of hematopoietic stem cell transplantation (HSCT). Here we report two patients... 
Veno-occlusive disease | VOD | Leukemia | Allogeneic Hematopietic stem cell transplantation | MULTIORGAN FAILURE | INFECTIOUS DISEASES | BONE-MARROW-TRANSPLANTATION | CHILDREN | SIGNIFICANT TOXICITY | COMPASSIONATE-USE | LIVER | HIGH-RISK POPULATION | COHORT | STEM-CELL TRANSPLANTATION | HEMATOLOGY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 9/2013, Volume 57, Issue 6, pp. 794 - 802
Background. The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)—related posttransplant... 
Health outcomes | Immunosuppression | Lymphoproliferative disorders | Mortality | Predisposing factors | Viral diseases | Transplantation | Graft vs host disease | Epstein Barr virus infections | ARTICLES AND COMMENTARIES | Blood | hematopoietic stem cell transplantation | risk factors | Epstein-Barr virus | post-transplant lymphoproliferative disorder | prognostic model | INFECTIOUS DISEASES | MANAGEMENT | PROGNOSTIC-FACTORS | LOAD | SCT | MICROBIOLOGY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | REACTIVATION | LYMPHOMA | PTLD | LYMPHOCYTES | Prognosis | Humans | Middle Aged | Child, Preschool | Infant | Epstein-Barr Virus Infections - surgery | Viral Load | Herpesvirus 4, Human - isolation & purification | Adult | Retrospective Studies | Child | Epstein-Barr Virus Infections - epidemiology | Lymphoproliferative Disorders - surgery | Epstein-Barr Virus Infections - virology | Lymphoproliferative Disorders - virology | Risk Factors | Kaplan-Meier Estimate | Europe - epidemiology | Hematopoietic Stem Cell Transplantation | Rituximab | Epstein-Barr Virus Infections - drug therapy | Lymphoproliferative Disorders - epidemiology | DNA, Viral - blood | Adolescent | Lymphoproliferative Disorders - drug therapy | Aged | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
Epilepsia, ISSN 0013-9580, 08/2016, Volume 57, Issue 8, pp. 1205 - 1214
Journal Article
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 01/2019, Volume 12, Issue 1, pp. 4 - 10